Westphal's Verastem files for IPO

Verastem Inc. (Cambridge, Mass.) proposed to raise up to $50 million in an IPO underwritten by UBS; Leerink; Lazard; Oppenheimer; and Rodman. The cancer stem cell company also disclosed in its S-1 that it raised $20.1M in a series C round this week. Verastem Chairman and CEO Christoph Westphal is the former co-founder and CEO of Sirtris Pharmaceuticals Inc., which went public in 2007 and was acquired by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in 2008. Westphal is the founder of Longwood Founders Fund and is slated to depart this year as president of GSK's venture arm, SR One. ...